Levosulpiride associated neuroleptic malignant syndrome in an
elderly patient: A tale of confusing brand names
Upinder Kaur1$, Kumudini Acharya2,
Amit Singh3, Indrajeet Singh
Gambhir4, Sankha Shubhra
Chakrabarti5#
1: MD, Department of Pharmacology, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India; Email:drupinder.bhu@gmail.com
2: MBBS, Department of Pharmacology, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India; E mail: kumudini91@gmail.com
3: MD, PhD, Department of Pharmacology, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India; Email: amit829@rediffmail.com
4: MD, Department of Geriatric Medicine, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India; Email id: iac2k10@gmail.com
5: MD, Department of Geriatric Medicine, Institute of Medical Sciences,
Banaras Hindu University, Varanasi, India
$: Co-corresponding author
#Corresponding author: Dr SS Chakrabarti
Email:
sankha.geriatrics@gmail.com
Phone: +919935615563
Word count : 1000
Table count : 1, Supplementary table: 1
Keywords: Geriatric pharmacovigilance, Levosulpiride,
extrapyramidal, neuroleptic malignant syndrome, D2 blocker.
What is already known about this subject : NMS is common with D2
blockers but rarely reported with Levosulpiride
What this study adds : NMS can occur with Levosulpiride. Drugs
with confusing brand names can be hazardous for elderly patients and
should be scrutinized.